4 ms·

Not mentioned in the article is the fact that lorlatinib, original studied in the phase 3 CROWN trial, was used in frontline management of advanced ALK-mutated

Not mentioned in the article is the fact that lorlatinib, original studied in the phase 3 CROWN trial, was used in frontline management of advanced ALK-mutated non-small cell lung cancer (NSCLC) [0]. Five-year data indicate a significant progression-free survival benefit, with 60% of patients free of progression. Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1]. It is the durability of progression-free survival that are most impressive and surprising here. That said, only 4% to 8% of patients with NSCLC will have ALK mutations/rearrangements, so while amazing, this finding is not applicable to all patients [2]. [0] https://www.nejm.org/doi/full/10.1056/NEJMoa2027187 https://www.nejm.org/doi/full/10.1056/NEJMoa2027187 [1] https://ascopubs.org/doi/10.1200/JCO.24.00581 https://ascopubs.org/doi/10.1200/JCO.24.00581 [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597761/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597761/

IG_Semmelweiss 2y ago
Can you elaborate? In particular, this: >>>>Five-year data indicate a significant progression-free survival benefit, with 60% of patients free of progression. So far im with you. >>>>Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1] This sounds awful? Or contradictory at best?
- ilya_m 2y ago
  >>>>Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1] > This sounds awful? Or contradictory at best? No, quite amazing. At 5 years more than 50% of participants are progression-free. That's indeed off the charts for a metastatic lung cancer.
- fredophile 2y ago
  I believe the median progression-free survival is the length of time where 50% of people are still free from progression. The numbers you mentioned would mean that we don't know how long that is for this treatment but it's definitely longer than 5 years. That sounds pretty good depending on the type of cancer and stage when treatment started.
- deleted 2y ago
  [deleted]

IG_Semmelweiss 2y ago

Can you elaborate? In particular, this: >>>>Five-year data indicate a significant progression-free survival benefit, with 60% of patients free of progression. So far im with you. >>>>Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1] This sounds awful? Or contradictory at best?

ilya_m 2y ago
>>>>Even after 60.2 months of follow-up, the median progression-free survival has not yet been reached [1] > This sounds awful? Or contradictory at best? No, quite amazing. At 5 years more than 50% of participants are progression-free. That's indeed off the charts for a metastatic lung cancer.
fredophile 2y ago
I believe the median progression-free survival is the length of time where 50% of people are still free from progression. The numbers you mentioned would mean that we don't know how long that is for this treatment but it's definitely longer than 5 years. That sounds pretty good depending on the type of cancer and stage when treatment started.
deleted 2y ago
[deleted]